FMC Corporation reports news on its global agricultural sciences business, including crop protection solutions, biologicals, crop nutrition, digital and precision agriculture, and research into herbicide, insecticide and fungicide active ingredients. Company updates commonly cover quarterly results, outlook commentary, dividend declarations, executive conference appearances, and regulatory approvals for products such as Isoflex® active.
FMC news also reflects the operating issues of a crop protection supplier, including regional revenue trends, product commercialization, operational priorities, capital-structure matters, and governance developments affecting its board and incentive plans.
FMC (FMC) submitted a regulatory dossier for its dual-mode herbicide rimisoxafen to Brazilian authorities for review. This is rimisoxafen's second global submission, following a July 2026 filing with the U.S. Environmental Protection Agency. It is the third novel herbicide active ingredient FMC has submitted for review in Brazil. Classified in herbicide Groups 12 and 32, rimisoxafen showed activity in FMC field testing against small-seeded broadleaf weeds, including resistant Amaranthus palmeri and Amaranthus hybridus.
FMC expects formulated-product submissions to follow as review advances. Rimisoxafen is not registered for sale or use in Brazil or any other country; timing and outcomes remain subject to regulatory review and approval.
FMC (FMC) and Tessenderlo Group announced the closing of an approximately $403 million minority equity investment on September 23, 2026. Tessenderlo Group purchased 30,319,166 shares of FMC common stock at $13.30 per share and now owns approximately 20.0% of FMC's outstanding common stock.
The companies entered into a definitive agreement on June 30, 2026, and satisfied all required closing conditions and regulatory approvals. Tessenderlo Group has the right to nominate one independent director to FMC's board and has nominated its chief executive officer, Luc Tack. Tessenderlo Group is subject to a three-year lock-up and agreed to standstill restrictions for as long as it owns FMC shares.
FMC Corporation (FMC) will release its third quarter 2026 earnings on Thursday, October 29, 2026, after the stock market close via PR Newswire and its investor website.
The company will host a public webcast conference call on Friday, October 30, 2026, at 9:00 a.m. ET. The event will be accessible via internet broadcast at the FMC investor relations site and by telephone for both U.S. and global participants.
FMC (FMC) and biotechnology firm AgroSpheres are advancing two proprietary RNA-based bioinsecticide candidates from discovery into global field trial development across the United States, Brazil and Asia. The biomolecules are designed to target some of the most persistent and economically damaging lepidopteran pests, including fall armyworm and diamondback moth, which together with a few other species drive nearly $14 billion in annual global crop losses and control costs.
The field trials follow several years of laboratory, greenhouse and small-scale field-plot testing, during which the candidates were benchmarked against industry-standard chemistries and, before being advanced, consistently met or exceeded that performance. The products are built on AgroSpheres’ biomodality and AgriCell encapsulation platforms, which use fermentation-based manufacturing and controlled-release delivery to protect biomolecules from UV exposure, heat and moisture while aiming for precise, pest-specific activity and reduced impact on beneficial insects.
FMC (NYSE: FMC) announced that chairman, chief executive officer and president Pierre Brondeau, and executive vice president and chief financial officer Andrew Sandifer, will present at the 2026 Jefferies Global Industrials Conference on September 10, 2026 at 11:30 a.m. Eastern Time.
A live webcast of FMC’s presentation will be available through the company’s investor website at www.fmc.com/investors.
Sabanto, a provider of autonomous tractor retrofit technology, appointed John M. Raines to its Board of Directors, following the close of an oversubscribed Series B funding round led by Leaps by Bayer with multiple agriculture-focused investors participating.
According to Sabanto, the new capital will be used to expand manufacturing and deployment, grow engineering and commercial teams, and invest further in its Vehicle Operating System (vOS) and Vehicle Mission Control (vMC) software. Raines brings more than 30 years of agriculture and technology leadership, including roles at TELUS Digital Agriculture & Consumer Goods, The Climate Corporation and Monsanto, and currently serves on the boards of FMC (NYSE: FMC), Sydenstricker Nobbe Partners, TPNB Bank/Paris Bancshares, and the University of Missouri Board of Curators.
FMC (NYSE:FMC) reported Q2 2026 revenue of $867 million, down 17% year over year; revenue excluding India was $841 million, down 20%. Organic revenue declined 22%. The company posted a GAAP net loss of $187 million (–$1.49 per share) and Adjusted EBITDA of $153 million, down 26%, with adjusted EPS of $0.26, down 62%.
GAAP cash from operations rose to $363 million and free cash flow to $357 million, helped by a $200 million rimisoxafen licensing upfront. FMC outlined about $1 billion of planned proceeds for debt reduction and lowered 2026 guidance: revenue to $3.50–$3.70 billion, Adjusted EBITDA to $620–$680 million, and adjusted EPS to $1.19–$1.49. The board concluded its strategic review and the company expects year-over-year growth to resume in Q4 2026.
FMC (NYSE: FMC) announced that its board of directors has declared a regular quarterly dividend of $0.08 per share. The dividend is payable on October 15, 2026 to shareholders of record at the close of business on September 30, 2026.
FMC (NYSE:FMC) has filed the first global regulatory submission for its new herbicide active ingredient rimisoxafen with the U.S. EPA. The dossier seeks approval for use on corn, soybean, sunflower and select pulse crops.
Rimisoxafen, discovered at FMC's Stine Research Center, is the first herbicide ever classified by HRAC as a dual mode of action active (Groups 12 and 32), inhibiting two weed biochemical pathways to help delay resistance. Extensive testing shows activity against troublesome weeds Palmer amaranth and waterhemp. This is FMC's third novel herbicide advanced to regulatory submission in recent years. Rimisoxafen is not yet registered or permitted for sale or use in any country.
FMC (NYSE:FMC) agreed to a $400 million strategic minority equity investment from Tessenderlo Group at $13.30 per share, giving Tessenderlo about 20% ownership. FMC plans to use proceeds toward its approximately $1 billion debt paydown target and has concluded its strategic options review.
Recent actions include a $1.2 billion secured high-yield bond, a $252 million sale of its India commercial business, a $200 million strategic supply and license agreement prepayment with Corteva, and a $114 million Newark sale-leaseback framework.